Introduction
============

Facial wrinkles and folds are the natural results of the aging process.[@b1-ccid-12-057] The decline of endogenous hyaluronic acid (HA) results in a less hydrated and consequently less elastic skin.[@b2-ccid-12-057] In the past 20 years, it has become increasingly common to use injectable soft tissue fillers to correct facial defects.[@b2-ccid-12-057],[@b3-ccid-12-057] HA-based dermal fillers have been proven to be safe, effective, and easy to use, thus becoming the most popular type of dermal fillers and widely used.[@b4-ccid-12-057],[@b5-ccid-12-057]

According to the statistics by the official website of the American Society for Aesthetic Plastic Surgery (ASAPS), the number of cases receiving HA injection for filling treatment was up to \>2.49 million in 2016, ranking second in the USA, only next to Botulinum toxin Type A in nonsurgical cosmetic procedures.[@b6-ccid-12-057]

Princess^®^ VOLUME (PV), manufactured by CROMA GmbH, is a highly cross-linked, viscoelastic, HA-injectable gel implant used for esthetic treatment, which received the CE mark in 2009. It has obtained market approval in the European Union and in 30 additional countries worldwide. PV filler is based on biofermentative HA crosslinking with 1,4-butanediol diglycidyl ether, which leads to an increased tissue residence.

To obtain China Food and Drug Administration approval, this clinical investigation evaluated the safety and effectiveness of PV for correction of moderate-to-severe nasolabial folds (NLFs) in Chinese subjects.

Methods
=======

Study design
------------

This was a prospective, split-face, randomized, evaluator and subject-blinded, multicenter, noninferiority trial. Eligible subjects were randomized to bilateral NLF treatment with the investigational medical device PV administered in one NLF and the comparator medical device Restylane^®^ (RL; Q-Med AB, Uppsala, Sweden) administered in the other NLF. The volume injected was chosen by the investigator and depended on the depth of wrinkle to be corrected. One touch-up treatment was possible at 2 weeks after initial treatment, if, per investigator's opinion, optimal correction was not achieved.

The study protocol conformed to the ethical guidelines of the Declaration of Helsinki and was approved by independent ethics committees of West China Hospital Sichuan University Clinical Trials and Biomedical Ethics Committee and the Ethics committee of the First Affiliated Hospital of Third Military Medical University.

Subjects
--------

The subjects were required to be aged between 30 and 65 years, without gender preference, and with approximately symmetrical NLFs of moderate (3) or severe (4) wrinkle severity score, as evaluated on the 5-point Wrinkle Severity Rating Scale (WSRS). Subjects signed informed consent before any procedure could take place and were excluded if they were pregnant, had serious skin diseases, facial surgery, or implantation of dermal fillers in the nasolabial region within the last 24 months, any type of facial or cosmetic procedure within the last 3--12 months, diabetes mellitus, uncontrolled systemic diseases, or tendency to keloid formation or were not suitable according to judgment of the investigator.

Assessments
-----------

Assessment for effectiveness was performed by the Independent Review Committee (IRC) and the investigators using the WSRS, and it was performed at 4, 12, and 24 weeks after injection.[@b7-ccid-12-057] Subjects and the IRC independently evaluated NLF improvement using the Global Aesthetic Improvement Scale (GAIS) at 4, 12, and 24 weeks after injection.[@b8-ccid-12-057] The GAIS is a 5-point scale used for rating the esthetic improvement of NLFs compared to pretreatment appearance. The ratings are worse (5 points), no change (4 points), improved (3 points), much improved (2 points), and very much improved (1 point).

Safety was evaluated throughout the whole study duration from the first application to the last visit at week 52. Subjects were also encouraged to spontaneously report adverse events (AEs) and were asked for any AE at each study visit.

Measures and endpoints
----------------------

The primary efficacy endpoint was the WSRS improvement rate for each NLF after 24 weeks relative to baseline, defined as the percentage of subjects who showed ≥1-point improvement for each NLF. The primary endpoint was a noninferiority comparison of responder rates for PV vs RL at 24 weeks. The secondary efficacy endpoints included the improvement rate based on subjects' and IRC's assessments of NLF improvement by using GAIS 4, 12, and 24 weeks after injection of PV compared with RL.

Statistical analysis
--------------------

The clinical investigation employs a noninferiority test for the primary endpoint analysis with a noninferiority margin of the WSRS improvement rate of 15% (Wald-type asymptotic test).[@b9-ccid-12-057]

The primary efficacy endpoint is the WSRS improvement rate at week 24 (Visit 7) relative to baseline (Visit 2).

"Effectiveness" is defined as the WSRS improvement rate ≥1. Subjects' evaluation of NLFs by using GAIS at 24 weeks compared to baseline was summarized, and the 95% CI was calculated for the GAIS scores for PV and RL.

The primary efficacy analysis was performed in the per-protocol (PP) population, defined as all subjects who were randomized, received treatment, had primary efficacy assessments at 24 weeks, and did not have any major protocol deviations.

Safety analyses were performed in the safety analysis (SA) population, defined as all subjects who received at least one treatment.

The full analysis set (FAS) comprises randomized subjects who received at least one administration of the investigational medical device and the control medical device and who had at least one evaluation of the efficacy endpoint at either 4, 12, or 24 weeks (Visits 5, 6, and 7, respectively) by the IRC.

Results
=======

Of the 120 subjects enrolled in the study, all were randomized and received all planned treatments and thus formed the FAS. Of these 120 subjects, 115 subjects completed the primary endpoint visit (24-week visit; 3 were lost to follow-up and 2 were overdue for more than 2 weeks). All subjects completed the 36- and the 52-week visits; therefore, 120 subjects were included in the SA. Product allocation was balanced between right and left NLFs.

Demographic and baseline characteristics
----------------------------------------

Most subjects were female (96.67%) with a mean age of 43 years (range 29--64 years) and a body mass index of 21.36 m^2^/kg. One hundred nineteen out of 120 subjects were Han Chinese.

Of the 120 subjects, 102 had a symmetrical WSRS severity score of 3, 16 had a symmetrical score of 4, and 2 had a score of 3 in one NLF and 4 in the other ([Table 1](#t1-ccid-12-057){ref-type="table"}).

At initial treatment, local anesthesia was administered identically for each NLF. The injection dose was similar between groups; median total volume injected (initial plus touch-up) was 1.00 mL for both products (range: PV 0.3--2.0 mL, RL 0.6--2.0 mL; [Table 2](#t2-ccid-12-057){ref-type="table"}).

Primary endpoint: IRC assessment of improvement rates at 24 weeks
-----------------------------------------------------------------

The IRC-evaluated improvement rates using WSRS at 24 weeks (PP population) were 68.70% for PV and 52.17% for RL, resulting in a difference of 95% CI of 8.20%, a value \<15%. PV was shown to be statistically noninferior to RL.

Noninferiority was also established in the FAS population (*p*=0.001).

At 24 weeks, 69.17% of subjects treated with PV and 53.33% of subjects treated with RL remained responders ([Figure 1](#f1-ccid-12-057){ref-type="fig"}).

Secondary endpoints: IRC and subject assessments of NLF score improvement over time
-----------------------------------------------------------------------------------

GAIS improvement over time was more favorable for PV than for RL. IRC-assessed GAIS change over time showed that the mean scores for PV were lower than the mean scores for RL, with a significant difference at 4 weeks (2.02 vs 2.11; *p*=0.012) and at 24 weeks (1.93 vs 2.05; *p*=0.007), for the FAS population, which remained similar for the PP population ([Figure 2](#f2-ccid-12-057){ref-type="fig"}). Subject-assessed mean improvement rates based on GAIS scores for PV were lower than the scores for RL at all time points, but without significant difference ([Figure 3](#f3-ccid-12-057){ref-type="fig"}).

Safety
------

Of the 120 subjects included in the SA population, 58 (48.33%) reported at least one AE for PV, and 53 (44.17%) reported at least one AE for RL ([Table 3](#t3-ccid-12-057){ref-type="table"}). Overall, the most frequently reported AEs for PV and RL were swelling (30.83% and 29.17%, respectively) and pain (21.67% and 23.33%, respectively). The incidence rates of AEs were similar in both groups. Overall, most AEs lasted for 14 days or less in 98.28% and 96.23% of subjects, who had a treatment site response to PV or RL, respectively.

Most of AEs related to PV and RL were mild (99.04% and 97.06%, respectively) in severity. All AEs associated with either product resolved without sequelae, and treatment with ice compression and massage was sufficient for the majority of AEs. There were no severe AEs in the clinical investigation.

Discussion
==========

The objective of the present study was to compare the efficacy and safety of PV vs RL. The efficacy of PV treatment for correction of moderate-to-severe NLFs in Chinese subjects was statistically noninferior to RL treatment; thus, the primary endpoint of this clinical investigation was successfully met. Correction was sustained through 24 weeks based on IRC assessment of improvement rates using the WSRS. The proportion of subjects with an improvement rate ≥1 point for PV was comparable to or better than for RL at 24 weeks, as evaluated by the IRC. The efficacy of RL observed in this study was consistent with previous reports.[@b12-ccid-12-057]--[@b14-ccid-12-057] In the study of Rzany et al, 78.8% of sides treated with RL had over 1 score improvement 6 months after injection.[@b13-ccid-12-057]

The mean GAIS scores for PV, as assessed by IRC and by subjects, were lower than those for RL at all time points, which are consistent with the result of WSRS improvement scores. These results indicate that PV is effective in reducing the severity of NLFs.

The median values were 1.00 mL in both treatment groups. The volume injected was chosen by the investigator and depended on the depth of NLF to be corrected. Median volumes used in the current investigation were similar to volumes used in the RL efficacy study in Chinese subjects for correction of severe NLFs (1.00 mL).[@b10-ccid-12-057],[@b11-ccid-12-057]

Secondary endpoints included evaluation of WSRS improvement rate, WSRS improvement scores, and GAIS scores of subjects at weeks 4, 12, and 24, injection dose and frequency, and 2 point (or higher) improvements in WSRS scores. Evaluation of the secondary endpoints confirmed that the efficacy of PV is comparable to, or even better than, RL.

PV and RL had similar safety profiles in the current investigation. The AEs reported by subjects included erythema, swelling, pain, bruising, nodule, pruritus, tenderness, hemorrhage and others, which are the AEs most commonly reported after treatment with dermal fillers. Several reports on HA with RL reported the filler to be safe and well tolerated, with the majority of the subjects having transient and mild injection site reactions, even up to 12 months, follow-up.[@b13-ccid-12-057],[@b15-ccid-12-057],[@b16-ccid-12-057]

PV and RL achieved the best NLF correction effect at 4 weeks, as measured by the WSRS. Analytical results of mean GAIS score changes were in agreement with these results.

Conclusion
==========

This clinical investigation demonstrated that PV is safe and effective in correction of moderate-to-severe NLFs in Chinese subjects. No new safety signals were seen in this population compared with non-Asian subjects, indicating a similar and favorable risk--benefit profile. Additionally, the treatment with PV in this study demonstrated noninferiority to RL treatment (10% and 15% noninferiority was demonstrated with 95% CI) and consistently better response across all evaluation parameters and time points.
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###### 

Demographic and baseline characteristics

  Characteristic               Description
  ---------------------------- ----------------
  Age, years                   
  Mean (range)                 43.07 (29--64)
  Female, N (%)                116 (96.67)
  Nationality                  
  Han Chinese                  N=119
  Non-Han Chinese              N=1
  Medical history              
  WSRS severity score (1--5)   
  3 symmetrical                N=102
  4 symmetrical                N=16
  4 and 3                      N=2

**Abbreviation:** WSRS, Wrinkle Severity Rating Scale.

###### 

Treatment characteristics (safety population)

  Characteristics                       PV                RL
  ------------------------------------- ----------------- -----------------
  Initial treatment                     N=120             N=120
  Touch-up treatment                    N=1               N=1
  Injection volume, median (min, max)                     
  Total, mL                             1.00 (0.3, 2.0)   1.00 (0.6, 2.0)

**Abbreviations:** PV, Princess^®^ VOLUME; RL, Restylane^®^.

###### 

Incidence of treatment site AEs

  AE                                                               PV           RL
  ---------------------------------------------------------------- ------------ ------------
  Subjects comprised in the safety assessment population (n=120)                
  Subjects with any event, N (%)                                   58 (48.33)   53 (44.17)
  Type, N (%)                                                                   
   Swelling                                                        37 (30.83)   35 (29.17)
   Pain                                                            26 (21.67)   28 (23.33)
   Injection site hemorrhage                                       14 (11.67)   15 (12.50)
   Injection site nodules                                          20 (16.67)   13 (10.83)
   Postoperative wound complications                               3 (2.5)      4 (3.33)
   Wound complication                                              1 (0.83)     1 (0.83)
   Postprocedural hemorrhage                                       0 (0.00)     2 (1.67)

**Abbreviations:** AE, adverse event; PV, Princess^®^ VOLUME; RL, Restylane^®^.
